Codexis Inc Stock Price, News & Analysis

Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and provide a business update.

Investors can access the live webcast on the Codexis Investor Relations website; the webcast will be archived for 90 days. A telephone replay will be available for 48 hours with access ID 13726635.

Codexis (NASDAQ:CDXS), a provider of enzymatic solutions for therapeutic manufacturing, announced its participation in the upcoming Cantor Global Healthcare Conference. The event will take place from September 3-5, 2025, in New York.

The company's management will engage in a fireside chat on September 4, 2025, at 3:55 pm ET. Investors can access a live webcast through Codexis's investor relations website, with a replay available for 90 days after the event.

Codexis (NASDAQ: CDXS) reported strong Q2 2025 financial results with revenue of $15.3 million, surpassing analyst estimates of $14.1 million. The company strengthened its cash position by raising $27.3 million through ATM facility and Innovatus loan to support its ECO Synthesis platform expansion.

Key financial metrics include a 72% product gross margin (up from 45% in Q2 2024), R&D expenses of $13.8 million, and a net loss of $13.3 million ($0.16 per share). The company ended Q2 with $66.3 million in cash and equivalents.

Notably, Codexis' ECO Synthesis platform was featured in six presentations at TIDES USA, including three from CDMO collaborators, demonstrating strong external validation. The company now has over 30 opportunities in various stages and expects to achieve pilot-scale production of GLP-grade siRNA material in 2025.

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutic manufacturing, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.

The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates. Investors can access the webcast through Codexis' Investor Relations website, where it will remain available for 90 days. For the live call, participants can dial 877-705-2976 (domestic) or 201-689-8798 (international).

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place from June 3-5, 2025 in New York.

The company's management will engage in a fireside chat on June 4, 2025, at 3:10 pm ET. Investors can access a live webcast of the presentation through Codexis's investor relations website, with a replay available for 90 days after the event.

Codexis (NASDAQ: CDXS) reported Q1 2025 financial results with total revenues of $7.5 million, down from $17.1 million in Q1 2024. The company secured its first revenue-generating contract for ECO Synthesis™ manufacturing services and maintained a strong cash position of $59.8 million. Net loss widened to $20.7 million ($0.25 per share) compared to $11.5 million ($0.16 per share) in Q1 2024. Product gross margin improved to 55% from 49% year-over-year. The company reiterated its 2025 guidance with expected total revenues of $64-68 million and anticipates reaching positive cash flow by the end of 2026. Notable achievements include successful development of first-generation ECO Synthesis enzymes and new board appointments. The company expects to achieve pilot scale production of GLP-grade siRNA material and sign a GMP scale-up partner by end of 2025.

Codexis (NASDAQ: CDXS) has announced six presentations featuring its ECO Synthesis Platform at the upcoming TIDES USA annual meeting in San Diego from May 19-22, 2025. The company will showcase data demonstrating the scalability and reproducibility of its enzymatic siRNA manufacturing processes through two oral presentations and one poster.

Key presentations will focus on: oligonucleotide CMC for sustainable siRNA manufacturing, comparative analysis of diastereomeric distribution in siRNA synthesis, and machine learning-guided ligation fragment design. Additionally, three CDMOs will present data on Codexis' double-stranded RNA ligases, including a co-presentation with Bachem.

The company will host a conference call on May 22, 2025, at 8:00 am ET to discuss the presented data. Attendees can visit Codexis at Booth #619, with advance appointments available through their website.

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after market close.

The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial performance and provide business updates. Investors can access the live webcast through the Codexis Investor Relations website, where it will remain available for 90 days.

For those preferring telephone access, the live call can be joined by dialing:

• Domestic: 877-705-2976
• International: 201-689-8798

A 48-hour telephone replay will be available using:

• Domestic: 877-660-6853
• International: 201-612-7415
• Access ID: 13726635

Codexis (NASDAQ: CDXS) announced that Byron Dorgan will retire from its Board of Directors at the 2025 Annual Meeting of Stockholders. Dorgan, who joined the Board in 2011 and served as Chairman from 2021 through 2024, currently chairs the Nominating and Corporate Governance Committee.

Following his departure, Dorgan will continue as a consultant to Codexis for one year. The company will reduce its Board seats from ten to nine. During his tenure, Dorgan contributed to Codexis's transformation into a leading therapeutics manufacturing company, particularly in advancing solutions like the ECO Synthesis platform.